Alkermes

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alkermes and other ETFs, options, and stocks.

About ALKS

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL.

CEO

Richard F. Pops

CEORichard F. Pops

Employees

2,050

Employees2,050

Headquarters

Dublin, Dublin

HeadquartersDublin, Dublin

Founded

2011

Founded2011

Employees

2,050

Employees2,050

ALKS Key Statistics

Market cap

7.32B

Market cap7.32B

Price-Earnings ratio

47.54

Price-Earnings ratio47.54

Dividend yield

—

Dividend yield—

Average volume

2.17M

Average volume2.17M

High today

$44.57

High today$44.57

Low today

$42.14

Low today$42.14

Open price

$43.05

Open price$43.05

Volume

1.14M

Volume1.14M

52 Week high

$44.57

52 Week high$44.57

52 Week low

$25.17

52 Week low$25.17

Stock Snapshot

As of today, Alkermes(ALKS) shares are valued at $43.91. The company's market cap stands at 7.32B, with a P/E ratio of 47.54.

During the trading session on 2026-06-04, Alkermes(ALKS) shares reached a daily high of $44.57 and a low of $42.14. At a current price of $43.91, the stock is +4.2% higher than the low and still -1.5% under the high.

Trading volume for Alkermes(ALKS) stock has reached 1.14M, versus its average volume of 2.17M.

The stock's 52-week range extends from a low of $25.17 to a high of $44.57.

ALKS News

Investing.com 6h

Alkermes to present narcolepsy drug data at SLEEP 2026 - Investing.com

...

TipRanks 6h

Alkermes to present new data on Alixorexton, LUMRYZ

Alkermes (ALKS) announced plans to present new data from its industry-leading portfolio of sleep medicine research at SLEEP 2026, the 40th annual meeting of the...

Simply Wall St 2d

Is Alkermes’ New LYBALVI Real-World Data Quietly Reframing Its Psychiatry Investment Story?

In May 2026, Alkermes plc reported that it had presented new clinical and real-world evidence on its psychiatry portfolio, LYBALVI and ARISTADA, alongside sleep...

Analyst ratings

81%

of 16 ratings

Buy

81.3%

Hold

18.8%

Sell

More ALKS News

TipRanks 6d

Alkermes Insider Makes Major Move in Latest Stock Transaction

New insider activity at Alkermes ( (ALKS) ) has taken place on May 29, 2026. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ra...

Simply Wall St 7d

Assessing Alkermes Valuation After New Clinical And Real World Data On Key Psychiatry Drugs

Alkermes (NasdaqGS:ALKS) has drawn fresh attention after presenting new clinical and real world data on LYBALVI and ARISTADA at major psychiatry and health econ...

TipRanks 7d

Needham Reiterates Buy Rating on Alkermes as Preclinical ALKS 7290 Data Support Unchanged $50 Price Target

Ami Fadia, an analyst from Needham, maintained the Buy rating on Alkermes. The associated price target remains the same with $50.00. Unlock trusted, data-backe...

People also own

Based on the portfolios of people who own ALKS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.